Quarterly ResultAug 5, 2026, 04:17 PM
Schrodinger Q2 Net Income $6.0M; Revenue $58.9M (+8%)
AI Summary
Schrodinger, Inc. reported strong second-quarter 2026 financial results, achieving a net income of $6.0 million, a significant improvement from a net loss of $43.2 million in the prior year. Total revenue increased 8% to $58.9 million, driven by a 27% rise in Annual Contract Value (ACV) to $29.6 million and a substantial increase in drug discovery revenue due to a collaboration milestone. The company also launched Bunsen, its new AI co-scientist, and secured a strategic software agreement with Bristol Myers Squibb, while raising its full-year drug discovery revenue guidance.
Key Highlights
- Net income was $6.0 million, compared to a net loss of $43.2 million in Q2 2025.
- Total revenue increased 8% year-over-year to $58.9 million.
- Annual Contract Value (ACV) grew 27% to $29.6 million.
- Drug discovery revenue was $23.0 million, including a $10 million milestone from Ajax Therapeutics acquisition.
- Operating expenses decreased 6% to $74.0 million.
- Other income was $48.9 million, primarily from a gain on the Eli Lilly acquisition of Ajax Therapeutics.
- Launched early access version of Bunsen, an agentic AI co-scientist for molecular discovery.
- Entered a strategic software agreement with Bristol Myers Squibb to deploy Bunsen.
- Full-year 2026 ACV guidance is $218 million to $228 million, representing 10-15% growth.
- Full-year 2026 drug discovery revenue guidance raised to $65 million to $75 million.
Price Impact
More from SDGR